Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
16-30 of 362

Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression
MinuteCE®Navigating Treatment Selection After First-line CDK4/6 Inhibitor Progression

The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape
MinuteCE®The Sequencing Puzzle: Integrating Oral SERDs and PROTACs into the mBC Treatment Landscape

Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens
MinuteCE®Translating Safety Data Into Practice: Effective AE Management in Oral SERD and PROTAC Regimens

Secondary Stroke Prevention: Antithrombotic Strategies for Neurologists, Hematologists, and Cardiologists
CME/CESecondary Stroke Prevention: Antithrombotic Strategies for Neurologists, Hematologists, and Cardiologists

CELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
CME/CECELMoDs in Multiple Myeloma: Optimizing RRMM Treatment With Potent Immunomodulatory Drugs
- advertisement

Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma
MinuteCE®Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients With Multiple Myeloma

Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
MinuteCE®Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma

Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients
MinuteCE®Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Eligible Patients

Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients
MinuteCE®Case Consult: Implementing Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients

Menin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice
CME/CEMenin Inhibitors in AML: Six Clinical Showdowns That Shape Real-World Practice

Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
MinuteCE®Case Consult: Targeting CDH6 in Platinum-Resistant Ovarian Cancer
- advertisement

Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer
MinuteCE®Case Consult: Personalizing First-Line Maintenance Therapy in Advanced Ovarian Cancer

Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer
MinuteCE®Case Consult: Treatment Strategies for HER2-Positive Platinum-Resistant Ovarian Cancer

Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer
MinuteCE®Case Consult: PD-L1–Guided Treatment Decisions in Platinum-Resistant Ovarian Cancer







































